Henan Tianfu Chemical Co., Ltd.

Pharmaceutical Agrochemicals Food Additives Synthetic Flavours & Fragrances Plant Extract Adhesive and Sealant Catalyst and Auxiliary Dyestuff and Pigment Materials Basic Inorganic Chemicals Organic Chemicals Others Reagent

Henan Tianfu Chemical Co., Ltd.

Country: China (Mainland)Business Type: Lab/Research institutions

Manufacturer

Assessed supplierAssessed
supplier

qq

    x
  • Mr.Nolan
  • Ms. Jane Kong

Contact US
Mr.Anson
Tel: 86-371-55170693/55170694
Ms.Fan Cindy
Tel: +86 0371 5517 0693
Mr.Richard Ran
Tel: 86 371 55170693
Ms.Anna
Tel: +86 -371 5517 0693
Mr.Nolan
Tel: 0371-55170695
Mr.Jeff Pei
Tel: 0371-55170693
Ms.Alice
Tel: :+86-371-5517 0693
Mr.Anson
Tel: 0371-55170693-8638
Ms.Monica Xie
Tel: 86 0371 5517 0693(147)
Ms.Cherry Zhang
Tel: 0086-371-55170690
Ms.Daisy He
Tel: 371-55170693
  • Fax: 86-371-55170690
  • URL: http://www.tianfuchem.com
  • Province/state: Henan
  • City: Zhengzhou
  • Street:Zhengzhou International Trade New Territory,Jinshui District,Zhengzhou ,China
  • MaxCard:
Home > Products > 

1032900-25-6 Ceritinib (LDK378)

1032900-25-6 Ceritinib (LDK378) CAS NO.1032900-25-6

  • FOB Price: USD: 1,000.00-1,000.00 /Metric Ton Get Latest Price
  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T
  • Available Specifications:

    pharma(0-1)Metric Ton

  • Product Details

Keywords

  • 1032900-25-6
  • Ceritinib (LDK378)
  • C28H36ClN5O3S

Quick Details

  • ProName: 1032900-25-6 Ceritinib (LDK378)
  • CasNo: 1032900-25-6
  • Molecular Formula: C28H36ClN5O3S
  • Appearance: white powder
  • Application: pharma
  • DeliveryTime: prompt
  • PackAge: as clients needs
  • Port: Shanghai,QingdaoTianjin,Guangzhou
  • ProductionCapacity: 1 Metric Ton/Day
  • Purity: 99%
  • Storage: RT
  • Transportation: sea
  • LimitNum: 1 Kilogram
  • Moisture Content: N/A
  • Impurity: N/A
  • N/A: N/A

Superiority

Our company was built in 2009 with an ISO certificate.In the past 6 years, we have grown up as a famous fine chemicals supplier in China and we had established stable business relationships with Samsung,LG,Merck,Thermo Fisher Scientific and so on.Our main business covers the fields below:
 
 
 
1.Noble Metal Catalysts (Pt.Pd...)
 
2.Organic Phosphine Ligands (Tert-butyl-phosphine.Cyclohexyl-phosphine...)
 
3.OLED intermediates (Fluorene,Carbazole,Boric acid...)
 
4.Customs Synthesis
 
 
 
Our advantage:
 
 
 
1. Higest quality and good package
 
2.Fast delivery
 
3.Better payment term
 
4.Fast response to customer  within 6 hours
 
5.Good business credit in Europe ,US ,Japan ,Korea
 
 
 
Anyway ,if you need any chemicals from China ,Henan Tianfu can help you

Details

Ceritinib (LDK378) Usage And Synthesis 
Indications and Usage Ceritinib is a new ALK gene inhibitor (ALKi) developed by Novartis Pharmaceuticals; its commercial name is Zykadia, and its previous code was LDK378. It was approved by the FDA for sale on April 29, 2014, and it is used to treat anaplastic lymphoma kinase (ALK) positive transfer of crizotinib (CRZ) progress or intolerance of non-small cell lung cancer (NSCLC). 
Mechanisms of Action Crizotinib resistance is a major issue for patients undergoing treatment for ALK gene rearrangement positive non-small cell lung cancer. Ceritinib is a kind of ALK tyrosine kinase inhibitor. Ceritinib does not target the MET proto-oncogene, but instead inhibits the insulin-like growth factor 1 receptor and blocks proteins from promoting cancer cell development, thus inhibiting the expression of EML4-ALK and NPM-ALK fusion protein cells. It is used to treat ALK rearrangement positive NSCLC patients who have previously used Crizotinib and can overcome Crizotinib resistance. Compared to Crizotinib, Ceritinib does not inhibit MET kinase activity, but inhibits IGF-1 receptors. Whether in terms of enzyme reaction, cell analysis or Crizotinib resistant animal models, research results all show that Ceritinib is more effective than Crizotinib. Additionally, regardless of any ALK resistance mutation, Ceritinib is still highly effective. In clinical models, Ceritinib’s ALK inhibition has 20 times the tumor-fighting effect of Crizotinib. Ceritinib also has the same effect on Crizotinib resistant central nervous system lesion NSCLC. Clinical trials show that Ceritinib can effectively inhibit ALK targets, potentially affecting an unknown kinase related to drug resistance, thus overcoming Crizotinib resistance. 
Patents American patent numbers: US7153964,US7893074,US7964592,US8039474,US8039479,US8377921,US8703787.
Patent expiration dates:
February 26, 2021 (US7153964)
April 25, 2026 (US7893074)
January 13, 2027 (US7964592)
June 29, 2030 (US8039474, US8039479)
November 20, 2027 (US8377921)
 
 
 
 

 

Other products of this supplier